Peptides DB
Research-centric peptide and protocol reference hub
Study 24 of 27GHK-Cu literatureScience (New York, N.Y.)Top journal1996

The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I).

Not reported in abstract.

Read at Science (New York, N.Y.)Add to compare

Where it sits

this study against the rest of the ghk-cu corpus
11
Preclinical · this one
14
Observational
0
Open-label
0
Randomised
2
Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
1996

Abstract

The authors’ words, as Science (New York, N.Y.) supplied them

The transition metal ion copper(II) has a critical role in chronic neurologic diseases. The amyloid precursor protein (APP) of Alzheimer's disease or a synthetic peptide representing its copper-binding site reduced bound copper(II) to copper(I). This copper ion-mediated redox reaction led to disulfide bond formation in APP, which indicated that free sulfhydryl groups of APP were involved. Neither superoxide nor hydrogen peroxide had an effect on the kinetics of copper(II) reduction. The reduction of copper(II) to copper(I) by APP involves an electron-transfer reaction and could enhance the production of hydroxyl radicals, which could then attack nearby sites. Thus, copper-mediated toxicity may contribute to neurodegeneration in Alzheimer's disease.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the GHK-Cu corpus

DGHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.Pharmaceutics · 2026 · Not reported in abstract.reviewDA Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials.Archives of internal medicine research · 2026 · Not reported in abstract.reviewDGrowth-modulating plasma tripeptide may function by facilitating copper uptake into cells.Nature · 1980—DThe Regenerative Potential of GHK-Cu in Aesthetic Medicine.Aesthetic surgery journal · 2026 · Not reported in abstract.reviewDDefining biomaterial-driven design principles for bioabsorbable flow diverters: current state and perspectives.Bioactive materials · 2026 · Not reported in abstract.reviewCA brain-targeted biomimetic iron-porphyrin covalent organic framework nanoplatform for Alzheimer's disease: synergistic intervention via antioxidant, Aβ-regulating and immunomodulatory effects.Journal of colloid and interface science · 2026 · Copper-ion chelation rate of 41.78%.In vitro